常见神经科药物自付费用持续上涨
该研究利用2004至2016年大型私人保险理赔数据库,分析多发性硬化、周围神经病、癫痫、痴呆和帕金森病患者的神经科药物自付费用。结果显示多发性硬化药物月均自付费用从2004年15美元升至2016年309美元,高免赔额保险计划患者的自付费用约为其他计划的两倍,提示神经科医生在治疗决策中需要精确的费用信息。
要点
- 多发性硬化药物月均自付费用从2004年15美元升至2016年309美元。
- 高免赔额计划患者月自付费用约为其他计划的两倍。
- 多发性硬化两年累计自付费用为2238美元,癫痫为230美元。
核心结论
- 过去12年神经科药物自付费用大幅增加,高免赔额计划患者负担尤重。
- 自付费用在不同疾病之间及同一疾病内部分布差异很大。
- 神经科医生在治疗决策中需要获取精确的费用信息以减轻患者经济负担。
研究设计与样本
- 利用2004至2016年大型私人保险理赔数据库,纳入门诊神经科医生诊治的多发性硬化、周围神经病、癫痫、痴呆和帕金森病患者。
- 研究比较了高免赔额健康计划与传统计划患者的自付费用。
- 研究探索了诊断后最初2年多发性硬化(高费用药物)与癫痫(低/中等费用药物)的累计自付费用。
主要发现
- 研究人群包括多发性硬化105355例、周围神经病314530例、癫痫281073例、痴呆120720例和帕金森病90801例。
- 多发性硬化药物月均自付费用上升最快,从2004年均值15美元(标准差23美元)升至2016年309美元(标准差593美元),不同药物间差异极小。
- 其他疾病中品牌药的自付费用也显著上升。
- 2016年高免赔额计划患者月自付费用约为其他计划的两倍:多发性硬化661美元(标准差964美元)对246美元(标准差472美元),癫痫40美元(标准差94美元)对18美元(标准差46美元)。
- 多发性硬化2年累计自付费用为2238美元(标准差3342美元),癫痫为230美元(标准差443美元),随时间几乎线性增长。
临床怎么用
- 神经科医生在为患者选择药物时应考虑其保险计划类型,尤其是高免赔额计划可能带来更高经济负担。
- 治疗决策中应主动获取并参考精确的药物自付费用信息,以帮助减轻患者经济压力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine out-of-pocket costs for neurologic medications in 5 common neurologic diseases. METHODS: Utilizing a large, privately insured, health care claims database from 2004 to 2016, we captured out-of-pocket medication costs for patients seen by outpatient neurologists with multiple sclerosis (MS), peripheral neuropathy, epilepsy, dementia, and Parkinson disease (PD). We compared out-of-pocket costs for those in high-deductible health plans compared to traditional plans and explored cumulative out-of-pocket costs over the first 2 years after diagnosis across conditions with high- (MS) and low/medium-cost (epilepsy) medications. RESULTS: The population consisted of 105,355 patients with MS, 314,530 with peripheral neuropathy, 281,073 with epilepsy, 120,720 with dementia, and 90,801 with PD. MS medications had the fastest rise in monthly out-of-pocket expenses (mean [SD] $15 [$23] in 2004, $309 [$593] in 2016) with minimal differences between medications. Out-of-pocket costs for brand name medications in the other conditions also rose considerably. Patients in high-deductible health plans incurred approximately twice the monthly out-of-pocket expense as compared to those not in these plans ($661 [$964] vs $246 [$472] in MS, $40 [$94] vs $18 [$46] in epilepsy in 2016). Cumulative 2-year out-of-pocket costs rose almost linearly over time in MS ($2,238 [$3,342]) and epilepsy ($230 [$443]). CONCLUSIONS: Out-of-pocket costs for neurologic medications have increased considerably over the last 12 years, particularly for those in high-deductible health plans. Out-of-pocket costs vary widely both across and within conditions. To minimize patient financial burden, neurologists require access to precise cost information when making treatment decisions.
引用
- Callaghan BC, Reynolds E, Banerjee M, et al. Out-of-pocket costs are on the rise for commonly prescribed neurologic medications. Neurology. 2019. PMID: 31043472. doi:10.1212/WNL.0000000000007564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。